Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.63 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731010 | 0.84 | NAPRT (0.67) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL1315187 | 0.83 | NAPRT (0.59) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL425117 | 0.79 | NAPRT (0.72) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL8193694 | 0.79 | NAPRT (0.72) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL440492 | 0.77 | NAPRT (1.00) | NAPRTDAOAURKAAURKBINCENP | |
| Hydrochloric Acid SCHEMBL17597625 | 0.76 | NAPRT (0.96) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL8077362 | 0.76 | NAPRT (0.67) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL3182033 | 0.76 | NAPRT (0.67) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL82637 | 0.76 | NAPRT (0.67) | NAPRTDAOAURKAAURKBINCENP | |
| SCHEMBL2281551 | 0.76 | NAPRT (0.67) | NAPRTDAOAURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | claimed |
| WO-2023250107-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | DENALI THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4244225-A1 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-4126861-A1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022101184-A1 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021198020-A1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-07 | — | — | WO | disclosed |
| US-10640494-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof | NORTHEASTERN UNIVERSITY (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2019217977-A1 | N-ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE (NAAA) INHIBITORS AND USE THEREOF | NORTHEASTERN UNIVERSITY (US) | 2019-11-14 | — | — | WO | disclosed |
| EP-3541802-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3469073-A1 | RAAV WITH CHEMICALLY MODIFIED CAPSID | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-04-17 | — | — | EP | disclosed |
| EP-1133493-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001044212-A1 | BENZOIC ACID ESTERS OF OXAZOLIDINONES HAVING A HYDROXYACETYLPIPERAZINE SUBSTITUENT | PHARMACIA & UPJOHN COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000032599-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0988060-A2 | ACID-LABILE AND ENZYMATICALLY DIVISIBLE DYE COMPOUNDS FOR DIAGNOSIS WITH NEAR INFRARED LIGHT AND FOR THERAPY | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 2000-03-29 | — | — | EP | disclosed |
| EP-0984947-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054161-A9 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998054161-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998047538-A2 | ACID-LABILE AND ENZYMATICALLY DIVISIBLE DYE COMPOUNDS FOR DIAGNOSIS WITH NEAR INFRARED LIGHT AND FOR THERAPY | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1998-10-29 | — | — | WO | disclosed |
| EP-0638082-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0638082-A4 | MACROCYCLIC IMMUNOMODULATORS. | ABBOTT LAB (US) | 1994-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640494-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof | NAAA, NAT1, NAALAD2 | NAPRT 199/4885DAO 111/4885AURKA 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.